10-Q: Autonomix Medical Reports Wider Losses, Nasdaq Delisting Risk

Autonomix Medical, Inc. reported increased net losses and significant cash burn in its latest quarterly filing, raising substantial doubt about its ability to continue as a going concern, while also facing a Nasdaq delisting notice.

Summary

• Net loss for the three months ended December 31, 2025, was $3.261 million, compared to $2.712 million for the same period in 2024.
• Net loss for the nine months ended December 31, 2025, was $14.049 million, compared to $8.219 million for the same period in 2024.
• Research and development expenses increased by 65% to $1.724 million for the three months ended December 31, 2025, and by 79% to $5.684 million for the nine months ended December 31, 2025, primarily due to clinical trials and product development.
• General and administrative expenses decreased by 5% to $1.619 million for the three months ended December 31, 2025, but increased by 67% to $8.613 million for the nine months ended December 31, 2025, largely due to accelerated stock-based compensation from option cancellations and higher legal fees.
• Cash and cash equivalents stood at $9.9 million as of December 31, 2025, with an accumulated deficit of $64.4 million.
• Current cash resources are estimated to fund operations only into but not beyond the third calendar quarter of 2026.
• The company received gross proceeds of approximately $5.0 million from a private placement of pre-funded and Series C warrants in November 2025.
• A Nasdaq deficiency letter was received on January 14, 2026, due to the common stock closing below the minimum $1.00 bid price requirement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning report due to significantly increased losses, accelerated cash burn, a short cash runway, explicit going concern doubts, and a Nasdaq delisting notice, despite some positive clinical and patent developments.

Positives

• Successfully completed key verification and validation activities for the ablation catheter in preparation for human use.
• Continued enrollment in the second proof-of-concept (PoC 2) human clinical study, expanding to include patients with other visceral cancers and earlier-stage pancreatic cancer.
• Positive clinical outcomes from the initial first-in-human PoC 1 study, demonstrating feasibility and safety of transvascular energy delivery and early clinical benefit in mitigating severe pancreatic cancer-related pain.
• Issuance of new U.S. Patent No. 12,369,852 (October 9, 2025) and European Patent No. EP4230133 (December 30, 2025) covering nerve-targeted therapies in cardiology, strengthening intellectual property.
• Two podium presentations at the Transcatheter Cardiovascular Therapeutics 2025 Annual Scientific Conference, highlighting early positive clinical findings.
• Successfully raised approximately $5.0 million in gross proceeds from a private placement of pre-funded and Series C warrants in November 2025.
• Successfully raised approximately $3.4 million in net proceeds from the At Market Issuances Sales Agreement (ATM Agreement) as of December 31, 2025.

Negatives

• Incurred significant net losses of $3.261 million for the three months and $14.049 million for the nine months ended December 31, 2025.
• Net cash used in operating activities rose substantially to $9.4 million for the nine months ended December 31, 2025, from $5.7 million in the prior year period.
• Accumulated deficit reached $64.4 million as of December 31, 2025.
• Current cash resources are estimated to be sufficient only into but not beyond the third calendar quarter of 2026, indicating a short cash runway.
• Management has identified substantial doubt about the company's ability to continue as a going concern within one year.
• Received a Nasdaq deficiency letter on January 14, 2026, for failing to maintain a minimum bid price of $1.00 per share, risking delisting.
• Material weaknesses in internal control over financial reporting persist, including lack of segregation of duties, general technology controls, and financial statement reporting.
• The company does not expect to generate positive cash flows from operating activities in the near future.
• The company does not intend to issue 271,846 shares requested by DTCC for fractional share rounding, which could lead to future disputes.

Risks

• Inability to raise additional capital when needed or on acceptable terms, which would adversely impact the ability to meet financial obligations and achieve business objectives.
• Substantial doubt about the company's ability to continue as a going concern within one year.
• Risk of delisting from Nasdaq due to non-compliance with the minimum bid price requirement, which could negatively affect financing, trading, value, and liquidity of common stock.
• Potential for significant dilution to current stockholders from future capital raising activities and the exercise/conversion of warrants.
• The investigational nature of the technology means there is no guarantee clinical trials will produce favorable outcomes or that products will receive regulatory approval.
• Challenges in scaling from current prototypes (hand-assembled, 3D-printed) to fully integrated commercial-grade devices.
• Material weaknesses in internal control over financial reporting (lack of segregation of duties, general technology controls, financial statement reporting) could lead to material misstatements.
• The sale of common stock by existing stockholders, or the perception of such sales, could cause the stock price to decline.
• Litigation risks, including potential claims related to the fractional share rounding issue.

Future Outlook

The company estimates its current cash resources are sufficient to fund operations only into but not beyond the third calendar quarter of 2026. It recognizes the need to raise an additional $30 million to $36 million to fund operations through commercialization of its first indication, including obtaining regulatory clearance and generating revenues. There is no assurance that additional financing will be available on acceptable terms, and a failure to raise sufficient capital would necessitate scaling back operations. The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its technology through development and clinical trials.

Management Comments

• "We estimate our current cash resources are sufficient to fund our operations into but not beyond the third calendar quarter of 2026."
• "We recognize it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development."
• "There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company."
• "A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company's ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives."
• "If the Company is unable to raise sufficient additional funds, it will have to scale back its operations."
• "We expect to incur increased research and development costs in the future as we continue with our clinical trials and product development costs."
• "Management believes its application of accounting policies, and the estimates inherently required therein, are reasonable."
• "Our CEO and CFO have concluded that, as of December 31, 2025, our disclosure controls and procedures were not effective."
• "Our management concluded that our internal control over financial reporting was, and continues to be, ineffective as of December 31, 2025 due to material weaknesses in our internal controls arising from a lack of segregation of duties; general technology controls; and financial statement reporting."
• "The Company does not believe the number of shares being requested [for fractional shares] is correct based on the historical number of shareholders of its common stock and is aware of similar anomalies in recent months for other companies completing a Reverse Stock Split. The Company does not intend to issue any shares in connection with the fractional shares and has concluded that an obligation should not be recorded in its financial statements."

Industry Context

StockSavvy.ai notes that Autonomix Medical operates in the highly competitive and capital-intensive medical device sector, specifically targeting neuromodulation for peripheral nervous system disorders. While the company's proprietary technology for real-time nerve signal detection and targeted energy delivery shows promise, particularly with positive early clinical data in pancreatic cancer pain and new patents in cardiology, its pre-revenue status and significant cash burn are typical challenges for clinical-stage life sciences companies. The need for substantial additional capital ($30M-$36M) for commercialization aligns with the high development costs in this industry, where regulatory hurdles and extensive clinical trials are standard. The expansion of the PoC 2 study to broader visceral cancers indicates a strategic move to diversify potential indications, a common approach for platform technologies to maximize market opportunity and de-risk single-indication reliance.

Management Changes

Corporate Governance

Legal Proceedings

• No material pending litigation.
• The company is not currently subject to any pending litigation as a result of the fractional share roundup shares.

Related Party Transactions

• On January 29, 2024, the company issued a warrant to purchase 80,000 shares to a licensee, a company controlled by a significant stockholder, pursuant to an Exclusive License Termination Agreement.
• In August 2025, 54,400 shares of this warrant were exercised on a cashless basis for 53,569 shares of the company's common stock.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future capital raises (warrants, ATM, Lincoln Park agreement). They also face potential delisting from Nasdaq, which could reduce liquidity and stock value. The reverse stock split, if implemented, aims to address delisting but can be perceived negatively.
• Employees/Management: Stock option cancellation agreements and severance terms were established for certain employees, Board members, and officers, indicating potential future workforce adjustments.
• Creditors: The "going concern" doubt raises concerns about the company's ability to meet its financial obligations.
• Customers/Partners: Continued clinical progress and patent issuances could be positive for future product adoption and partnerships, but the financial instability poses a risk to long-term development and commercialization.

Next Steps

• Continue clinical trials and product development for the catheter-based sensing and ablation system.
• Advance enrollment in the PoC 2 human clinical study.
• Refine catheter design to meet regulatory and manufacturing standards for human use.
• Seek additional financing of approximately $30 million to $36 million to fund operations to commercialization.
• Address Nasdaq minimum bid price deficiency by July 13, 2026, potentially through a reverse stock split.
• Implement and strengthen internal controls to address material weaknesses in segregation of duties, general technology controls, and financial statement reporting.
• Obtain regulatory clearance for products under development.
• Commercialize and generate revenues from products under development.

Key Dates

Recommendation

Autonomix Medical, Inc. faces severe financial distress, evidenced by rapidly increasing net losses, a substantial accumulated deficit, and a very short cash runway extending only into Q3 2026. The explicit 'going concern' warning from management, coupled with a Nasdaq delisting notice due to sub-$1.00 share price, signals critical operational and market challenges. While some clinical progress and patent grants are noted, these are overshadowed by the immediate and profound financial instability and governance issues (material weaknesses in internal controls). The need for significant additional capital ($30M-$36M) in the near term, with no assurance of availability on acceptable terms, makes the company a high-risk investment with a strong likelihood of further value erosion and potential failure to meet obligations.

Keywords

Medical Device, Neuromodulation, Peripheral Nervous System, Pancreatic Cancer Pain, RF Ablation, Clinical Stage, SEC Filing, 10-Q, Autonomix Medical, AMIX, Going Concern, Nasdaq Delisting, Capital Raise, Warrants, Clinical Trials, Intellectual Property, Cardiology, Hypertension, Arrhythmia Management, Heart Failure, Refractory Angina